US big biotechs lag in the opening quarter of the year
A look at sector share prices in the opening three months of 2019 reveals a resurgent big pharma and a strong showing from the world’s other large drug makers, with US…
China’s blueprint for a checkpoint blocker price war
A price war over anti-PD-(L)1 drugs is raging in China, less than a year after the first one was approved. When could the US see something similar?
Titan could give Erleada a fighting chance
But Erleada, Johnson & Johnson’s next-gen prostate cancer therapy, still needs to outperform the incumbent, Zytiga.
Pharma news over the Christmas period
If the recent performance of biotech stocks prompted you to pull down the shutters until the New Year celebrations subsided here’s what you might have missed.
Esmo 2018 – Adaptimmune gets the wooden spoon
The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.
Esmo 2018 – Without overwhelming efficacy the me-too PD-1 chase is futile
Results from Tesaro, Sanofi, Novartis, Merck KGaA and others have come in thick and fast, but can any beat the entrenched leaders?
Esmo 2018 preview – Another first-line renal cancer showdown
Once again Europe’s premier oncology meeting provides the perfect venue for big pharmas including Pfizer, Roche and Astrazeneca to showcase important pivotal study…
Asia wins 2017’s mid-cap race
A cooling of the M&A climate allows Asia-based groups to come to the fore.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.